Acute lymphocytic leukemia | Very Aggressive Non-Hodgkin Lymphoma | Burkitt Lymphoma | Burkitt-like lymphoma | Central nervous system leukaemia
Item
patients with acute lymphoblastic leukemia or very aggressive non-hodgkin-lymphoma (burkitt/burkitt-like) and cns relapse.
boolean
C0023449 (UMLS CUI [1])
C1332225 (UMLS CUI [2,1])
C0442824 (UMLS CUI [2,2])
C0006413 (UMLS CUI [3])
C1368771 (UMLS CUI [4])
C1332884 (UMLS CUI [5])
Central Nervous System Involvement
Item
cns involvement must be demonstrated by:
boolean
C4050309 (UMLS CUI [1])
Ventricular CSF Positive Cytology | Cerebrospinal Fluid Lumbar Positive Cytology | Cell count, cerebrospinal fluid
Item
a positive ventricular or lumbar csf cytology defined as csf cell counts > 5/µl (19/3 cells), obtained within 10 days prior to inclusion or
boolean
C1550320 (UMLS CUI [1,1])
C3846509 (UMLS CUI [1,2])
C0007806 (UMLS CUI [2,1])
C0024090 (UMLS CUI [2,2])
C3846509 (UMLS CUI [2,3])
C0427874 (UMLS CUI [3])
Neoplastic meningitis Signs and Symptoms | Involvement meningeal Magnetic Resonance Imaging | Involvement meningeal X-Ray Computed Tomography | Central nervous system leukaemia | Location Relapse | systemic therapy | Central Nervous System Agents | Methotrexate High dose | Ara-C High dose | Thiotepa
Item
characteristic signs and symptoms of neoplastic meningitis plus an mri or ct scan indicating the presence of meningeal involvement. patients with combined relapse in cns and other locations may be included in case that systemic therapy with cns active drugs (hdmtx;hdac, thiotepa) can be postponed for at least 2 weeks.
boolean
C1704231 (UMLS CUI [1,1])
C0037088 (UMLS CUI [1,2])
C1314939 (UMLS CUI [2,1])
C0521400 (UMLS CUI [2,2])
C0024485 (UMLS CUI [2,3])
C1314939 (UMLS CUI [3,1])
C0521400 (UMLS CUI [3,2])
C0040405 (UMLS CUI [3,3])
C1332884 (UMLS CUI [4])
C1515974 (UMLS CUI [5,1])
C0277556 (UMLS CUI [5,2])
C1515119 (UMLS CUI [6])
C0007680 (UMLS CUI [7])
C0025677 (UMLS CUI [8,1])
C0444956 (UMLS CUI [8,2])
C0733521 (UMLS CUI [9,1])
C0444956 (UMLS CUI [9,2])
C0039871 (UMLS CUI [10])
Karnofsky Performance Status
Item
karnofsky >60%
boolean
C0206065 (UMLS CUI [1])
Age
Item
age >18 years old
boolean
C0001779 (UMLS CUI [1])
Therapeutic procedure Resulting in Toxicity CTCAE Grades | Patient recovered | Haematotoxicity
Item
recovery from grade iii/iv toxicities attributable to prior treatment with the exception of hematotoxicity.
boolean
C0087111 (UMLS CUI [1,1])
C0332294 (UMLS CUI [1,2])
C0600688 (UMLS CUI [1,3])
C1516728 (UMLS CUI [1,4])
C1115804 (UMLS CUI [2])
C0920103 (UMLS CUI [3])
Cardiac dysfunction Severe Absent | Pulmonary Dysfunction Severe Absent | Liver Dysfunction Severe Absent | Renal dysfunction Severe Absent
Item
no severe heart, lung, liver or kidney dysfunction.
boolean
C3277906 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C1709770 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
C0086565 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C0332197 (UMLS CUI [3,3])
C3279454 (UMLS CUI [4,1])
C0205082 (UMLS CUI [4,2])
C0332197 (UMLS CUI [4,3])
Informed Consent | Informed Consent Guardian
Item
the patient or guardian must be competent to provide informed consent and must provide written informed consent prior to the initiation of study procedures
boolean
C0021430 (UMLS CUI [1])
C0021430 (UMLS CUI [2,1])
C1274041 (UMLS CUI [2,2])
Intrathecal therapy failed | Methotrexate Dose Quantity | Cytarabine Dose Quantity | Dexamethasone Dose Quantity | Cerebrospinal Fluid Clearance Absent
Item
failure (as defined by no clearance of the csf) to > 1 dose of prior intrathecal mtx or cytarabine or triple (mtx, arac, dexamethasone) therapy
boolean
C1831734 (UMLS CUI [1,1])
C0231175 (UMLS CUI [1,2])
C0025677 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C1265611 (UMLS CUI [2,3])
C0010711 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C1265611 (UMLS CUI [3,3])
C0011777 (UMLS CUI [4,1])
C0178602 (UMLS CUI [4,2])
C1265611 (UMLS CUI [4,3])
C0007806 (UMLS CUI [5,1])
C1382187 (UMLS CUI [5,2])
C0332197 (UMLS CUI [5,3])
Intrathecal therapy | Systemic therapy High dose | Neurotoxicity Severe CTCAE Grades | Peripheral Neuropathy Vincristine Induced
Item
history of previous severe neurotoxicity (grade iii-iv) attributed to intrathecal therapy or systemic high-dose therapy with methotrexate or cytarabine (vincristine induced peripheral neuropathy is accepted)
boolean
C1831734 (UMLS CUI [1])
C1515119 (UMLS CUI [2,1])
C0444956 (UMLS CUI [2,2])
C0235032 (UMLS CUI [3,1])
C0205082 (UMLS CUI [3,2])
C1516728 (UMLS CUI [3,3])
C0031117 (UMLS CUI [4,1])
C0042679 (UMLS CUI [4,2])
C0205263 (UMLS CUI [4,3])
Central nervous system leukaemia
Item
prior cns relapse < 1 month before
boolean
C1332884 (UMLS CUI [1])
Communicable Disease Uncontrolled
Item
uncontrolled infection
boolean
C0009450 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
Pregnancy | Breast Feeding | Childbearing Potential Urine pregnancy test negative | Childbearing Potential Serum pregnancy test negative | Childbearing Potential Contraceptive methods
Item
the patient must not be pregnant or breast feeding. if the patient is a female of child-bearing potential she must have a negative (urine or serum) pregnancy test and be using effective methods to prevent pregnancy
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C3831118 (UMLS CUI [3,1])
C0430057 (UMLS CUI [3,2])
C3831118 (UMLS CUI [4,1])
C0430061 (UMLS CUI [4,2])
C3831118 (UMLS CUI [5,1])
C0700589 (UMLS CUI [5,2])